Evidence map›Paper›PMID 40114486›Full record

ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2025

[Chinese Expert Consensus on Assessment and Clinical Application of 
Tertiary Lymphoid Structure for Non-small Cell Lung Cancer (2025 Version)].

Lung Cancer Collaboration Group of Tumor Pathology Committee of Chinese Anti-Cancer Association, Expert Committee on Non-small Cell Lung Cancer of Chinese Society of Clinical Oncology

Abstract readReviewEnglish AbstractConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Lung Cancer Collaboration Group of Tumor Pathology Committee of Chinese Anti-Cancer Association
Expert Committee on Non-small Cell Lung Cancer of Chinese Society of Clinical Oncology

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tertiary lymphoid structure (TLS) plays a crucial role in the tumor microenvironment, influencing tumor development and progression. As an emerging biomarker for predicting the prognosis and treatment response in cancer patients, TLS has received increasing attention. However, there is currently a lack of standardized evaluation criteria for TLS, and significant differences exist in TLS across different tumor tissues. This poses challenges for the clinical application of this biomarker in translation. To meet the clinical diagnosis and treatment needs of non-small cell lung cancer (NSCLC), this consensus focuses on the definition, clinical significance, testing components, and assessment methods of TLS in NSCLC. Combining relevant research and Chinese clinical practice, it provides standardized and normalized suggestions for the clinical assessment and application of TLS, so as to improve the understanding of TLS among clinicians and pathologists, and provide a reference basis for the clinical application of the detection of TLS in NSCLC. 
.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsTertiary Lymphoid StructuresChinaConsensusEast Asian PeopleHumansAssessmentClinical applicationConsensusLung neoplasmsTertiary lymphoid structure

Identifiers

PMID40114486
PMCPMC11931240

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.